This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Mylan Expresses Support For National HIV Testing Day

PITTSBURGH, June 27, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), today expresses its support for National HIV Testing Day, an annual campaign to encourage people of all ages to be proactive and know their HIV status. According to the Centers for Disease Control and Prevention (CDC), more than 1.1 million people in the U.S. are living with HIV and 1 in 5 does not know they are infected. Getting tested is the first step in taking control of your health.

CEO Heather Bresch commented, "About half of all new HIV infections in the U.S. are attributed to the 20% of HIV-positive individuals who do not know they are infected. Knowing your status is a powerful step toward lowering the rate of HIV infections and ultimately eliminating the disease altogether."

There are 50,000 new cases of HIV infection every year in the U.S., according to the CDC, and over half of these infections occur in people ages 12 to 34. Recent studies have shown that HIV-positive people who are on antiretroviral medications (ARVs) can expect to live a long and healthy life with no increased risk of mortality, and are 96% less likely to transmit the virus to others.

Bresch continued, "The U.S. Department of Health and Human Services guidelines state that all people living with HIV in the U.S. are eligible for life-saving ARVs regardless of their disease progression. Mylan is dedicated to helping those infected with HIV live life to its fullest potential by providing access to more affordable versions of these medications."

Knowledge is power in the fight against HIV/AIDS. To find a testing site near you, visit or text your zip code to KNOWIT (566948).

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of approximately 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside.

SOURCE Mylan Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs